About Us Resources Catalysts Start Free Trial →

Loading…

Day Trader Sniper provides algorithmic alerts and analysis, not trade advice.
Not financial advice. Trade at your own risk.

Quick Links

Download The App Resources Market Feed Stocks

Catalysts About Us Support Privacy policy Terms of use

©2026 Day Trader Sniper - all rights reserved

Home›Catalysts›Regulatory and Clinical

Catalyst Category

Regulatory and Clinical

Live feed of every catalyst classified under Regulatory and Clinical.

CATALYSTS IN FEED

168

AVG MAX MOVE

+116.8%

POSITIVE MOVES

100%

LARGEST MOVE

+664.1%

DSMB Efficacy Met FDA 510(k) Cleared FDA Approval FDA Fast Track FDA Meeting FDA Meeting Granted Generic Drug Approved Inconclusive Topline Results IND Cleared for Study IND Filed NDA Resubmission Orphan Drug Designation Positive Subgroup Data Positive Topline Results Primary Endpoint Met SPA Agreement Study Complete Trial Enrollment Complete

Range–

Showing 7 of 168

Regulatory and ClinicalFDA 510(k) ClearedJul 2, 2026 · 8:00am ET

TNONTenon Medical, Inc.

Tenon Medical Receives FDA 510(k) Clearance for Catamaran SI Joint Fusion System

The clearance allows for the marketing of the new medical device.

Be first on the next Regulatory and Clinical catalyst.

Day Trader Sniper alerts you the instant a setup like this triggers.

Download Free →

Max move

+59.6%

RVOL

5.4x

Max high

$17.07

Fuel

23m

Regulatory and ClinicalFDA 510(k) ClearedJul 2, 2026 · 8:00am ET

TNONTenon Medical, Inc.+59.6%

Tenon Medical Receives FDA 510(k) Clearance for Catamaran SI Joint Fusion System

RVOL

5.4x

Max high

$17.07

Fuel

23m

Regulatory and ClinicalPositive Topline ResultsJul 1, 2026 · 7:30am ET

ELABPMGC Holdings Inc.

NorthStrive Biosciences Announces Positive Phase III Results with Yuva Biosciences

Company reports successful outcomes from AI-driven drug discovery collaboration.

Regulatory and ClinicalPositive Topline ResultsJul 1, 2026 · 7:30am ET

ELABPMGC Holdings Inc.+53.7%

NorthStrive Biosciences Announces Positive Phase III Results with Yuva Biosciences

Regulatory and ClinicalPositive Topline ResultsJun 30, 2026 · 7:01am ET

KTTAPasithea Therapeutics Corp.

Pasithea Therapeutics Announced Updated Interim Safety and Clinical Activity Data for PAS-004

The data is from the trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors.

Regulatory and ClinicalPositive Topline ResultsJun 30, 2026 · 7:01am ET

KTTAPasithea Therapeutics Corp.+36.4%

Pasithea Therapeutics Announced Updated Interim Safety and Clinical Activity Data for PAS-004

Regulatory and ClinicalPositive Topline ResultsJun 29, 2026 · 6:16pm ET

VVOSVivos Therapeutics, Inc.

Vivos Therapeutics' Vida® Appliance Shows Improvement in Insomnia Severity for All Trial Patients

Company announces positive results from clinical trial.

Regulatory and ClinicalPositive Topline ResultsJun 29, 2026 · 6:16pm ET

VVOSVivos Therapeutics, Inc.+50.9%

Vivos Therapeutics' Vida® Appliance Shows Improvement in Insomnia Severity for All Trial Patients

Regulatory and ClinicalPositive Topline ResultsJun 23, 2026 · 8:11am ET

ICCMIceCure Medical Ltd.

IceCure Medical Highlights Published Article on Cryoablation Advantages

Company underscores clinical benefits in early-stage breast cancer treatment.

Regulatory and ClinicalPositive Topline ResultsJun 23, 2026 · 8:11am ET

ICCMIceCure Medical Ltd.+41.0%

IceCure Medical Highlights Published Article on Cryoablation Advantages

Regulatory and ClinicalIND FiledJun 11, 2026 · 7:02am ET

PPBTPURPLE BIOTECH LTD.

Purple Biotech Presented New Cancer Immunotherapy Data at EACR 2026

Company stated that IM1240 data support the first human study in 2027.

Regulatory and ClinicalIND FiledJun 11, 2026 · 7:02am ET

PPBTPURPLE BIOTECH LTD.+102.0%

Purple Biotech Presented New Cancer Immunotherapy Data at EACR 2026

Regulatory and ClinicalSPA AgreementJun 9, 2026 · 7:06am ET

ATHEALTERITY THERAPEUTICS LTD

Alterity Therapeutics Aligns with FDA on Phase 3 ATH434 Program

FDA agrees to Phase 3 design including UMSARS Part I as primary endpoint.

Regulatory and ClinicalSPA AgreementJun 9, 2026 · 7:06am ET

ATHEALTERITY THERAPEUTICS LTD+57.2%

Alterity Therapeutics Aligns with FDA on Phase 3 ATH434 Program

1
…
5
6
7
…
24

RVOL

6.5x

Max high

$18.90

Fuel

9m

RVOL

4.0x

Max high

$0.01

Fuel

7m

RVOL

6.8x

Max high

$0.70

Fuel

16m

RVOL

15.1x

Max high

$8.35

Fuel

2m

RVOL

3.5x

Max high

$5.98

Fuel

3m

RVOL

8.7x

Max high

$6.78

Fuel

1m